NCT04591002 is a Phase 2 clinical trial of Osimertinib 80 MG in Lung Cancer, sponsored by Samsung Medical Center.

Who is sponsoring NCT04591002?

NCT04591002 is sponsored by Samsung Medical Center.

What drugs are being tested in NCT04591002?

Interventions in NCT04591002: Osimertinib 80 MG.

What condition does NCT04591002 study?

NCT04591002 studies Lung Cancer.

Is NCT04591002 still recruiting?

NCT04591002 is currently recruiting now. Last updated 26 June 2025.

Last reviewed 2025-06-26 · How we verify

NCT04591002

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osimertinib to Suppress the Progression of GGN(EGFR Mutation-positive)

Recruiting now Phase 2 Last updated 26 June 2025

What this trial tests

Phase 2 trial testing Osimertinib 80 MG in Lung Cancer in 43 participants. Currently enrolling.

Timeline

26 July 2022

Primary endpoint
20 November 2025

30 October 2028

Quick facts

Lead sponsor	Samsung Medical Center
Phase	Phase 2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	43
Start date	26 July 2022
Primary completion	20 November 2025
Estimated completion	30 October 2028
Sites	2 locations across South Korea

Drugs / interventions tested

Osimertinib 80 MG — full drug profile →

Conditions studied

Lung Cancer — all drugs for Lung Cancer →

Sponsor

Samsung Medical Center

Who can join

Adults 30 to 75, any sex, with Lung Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study designed to assess the efficacy of osimertinib (80 mg, orally, once daily) to suppress the progression of remaining GGN(s) in other lobes following surgical resection for actionable EGFR mutation-positive stage I lung adenocarcinoma.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Osimertinib in EGFR-Mutated Lung Cancer: A Review of the Existing and Emerging Clinical Data.
Lee CS, Milone M, Seetharamu N. · · 2021 · cited 24× · PMID 34471361 · DOI 10.2147/ott.s227032

Verify or expand the search:

Other trials of Osimertinib 80 MG

Trials testing the same drug.

NCT07058519 — A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC · Phase 2 · recruiting
NCT06557096 — CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC · EARLY_PHASE1 · not yet recruiting
NCT05583409 — SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC · NA · unknown
NCT04184921 — Combination of Osimertinib and Aspirin to Treat EGFR Mutation NSCLC Patients · Phase 2 · completed
NCT04965701 — First Line Osimertinib in the Real World: an Inter-regional Prospective Study · completed

Other recruiting trials for Lung Cancer

Currently open trials in the same condition.

NCT07295821 — Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study · Phase 2 · recruiting
NCT06909201 — Hyperpolarized Xenon-129 Magnetic Resonance Imaging in Lung Cancer Patients Receiving Radiation Therapy for Investigatin · Phase 1 · recruiting
NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
NCT07487064 — Galvanize Aliya® EX Pulsed Electric Field (PEF) Treat and Resect Study · NA · recruiting
NCT07146568 — Evaluating the Implementation and Effectiveness of the Pink and Pearl Campaign on Lung Cancer Screening at Christian Hos · NA · recruiting

Other Samsung Medical Center trials

Trials by the same sponsor.

NCT07482865 — Routine Versus Provisional Distal Perfusion Catheter Placement in Patients Undergoing Mechanical Circulatory Support · NA · not yet recruiting
NCT07467213 — Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute M · Phase 4 · not yet recruiting
NCT07530913 — Effectiveness Analysis of a Rehabilitation Exercise Platform for Living Donor Liver Transplantation Patients · NA · enrolling by invitation
NCT07500701 — Salvage Moderate Hypofractionated Versus Ultrahypofractionated Radiotherapy for Biochemical Recurrence After Radical Pro · Phase 3 · recruiting
NCT07409441 — Korea Acute Myocardial Infarction Registry · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04591002 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Samsung Medical Center
Last refreshed: 26 June 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04591002.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing